PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
60.05%
R&D change of 60.05% while AGEN maintains spending. Bruce Berkowitz would investigate effectiveness.
231.77%
G&A growth while AGEN reduces overhead. John Neff would investigate operational differences.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
121.69%
Operating expenses growth 1.1-1.25x AGEN's 97.66%. Bill Ackman would demand justification.
-100.00%
Both companies reducing total costs. Martin Whitman would check industry trends.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both companies reducing D&A. Martin Whitman would check industry patterns.
-127.89%
EBITDA decline while AGEN shows 41.77% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-121.69%
Operating income decline while AGEN shows 48.60% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-17.94%
Other expenses reduction while AGEN shows 42.57% growth. Joel Greenblatt would examine advantage.
-139.60%
Pre-tax income decline while AGEN shows 45.90% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-139.60%
Net income decline while AGEN shows 44.79% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-131.82%
EPS decline while AGEN shows 51.87% growth. Joel Greenblatt would examine position.
-131.82%
Diluted EPS decline while AGEN shows 51.87% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.